GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Its stock price is a speculative bet on the success of its scientific research. The chart reflects the high volatility inherent in early-stage companies.
Share prices of companies in the market segment - Neuro
Coya Therapeutics is a biopharmaceutical company developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. We classify it as part of the Neuroscience sector. The chart below illustrates the overall performance of this innovative segment.
Broad Market Index - GURU.Markets
Coya Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative and autoimmune diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Coya shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
COYA - Daily change in the company's share price Coya Therapeutics Inc.
For Coya Therapeutics, Inc., a company focused on neurodegenerative diseases, daily price change is a measure of high volatility. It reflects the market's reaction to research data and is a key parameter in biotech risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Neuro
For Coya Therapeutics, Inc., a company focused on neurodegenerative diseases, daily price change is a measure of high volatility. It reflects the market's reaction to research data and is a key parameter in biotech risk assessment formulas.
Daily change in the price of a broad market stock, index - GURU.Markets
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Its shares are driven by news of clinical trials. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Coya Therapeutics Inc.
Coya Therapeutics, Inc.'s year-over-year performance is a story of developing regulatory T-cell (Treg) therapy for neurodegenerative diseases. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach could offer a new way to combat the inflammation underlying diseases like ALS.
Annual dynamics of market capitalization of the market segment - Neuro
Coya Therapeutics, Inc. is a clinical-stage biotech company developing therapies for neurodegenerative diseases. Its stock price is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Coya Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Coya Therapeutics Inc.
Coya Therapeutics is a clinical-stage biotech focused on neurodegenerative diseases. Its monthly performance is driven by news from its R&D pipeline. Data on its regulatory T-cell (Treg) therapy is a key driver of investor valuation.
Monthly dynamics of market capitalization of the market segment - Neuro
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and autoimmune diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it's possible to assess how its approach, based on regulatory T cells (Tregs), is progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Coya Therapeutics is a clinical-stage biotech focused on neuroscience. Its shares move not with the market, but in anticipation of research news. The chart shows monthly performance, which is determined entirely by progress in drug development, not by general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Coya Therapeutics Inc.
Coya Therapeutics, a clinical-stage biotech developing therapies for neurodegenerative diseases, is experiencing high volatility. Weekly stock performance is driven by news about clinical trials and research data, reflecting the risks and hopes in this complex field.
Weekly dynamics of market capitalization of the market segment - Neuro
Coya Therapeutics is developing a regulatory T-cell-based therapy for the treatment of neurodegenerative diseases. This chart compares its data-driven performance with overall trends in the neuroscience sector and assesses investor confidence in its innovative approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Coya Therapeutics is a clinical-stage biotech focused on neuroscience. Its stock exists in its own world, where research data is king. The chart shows that Coya's performance is largely uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
COYA - Market capitalization of the company Coya Therapeutics Inc.
Coya Therapeutics' stock price is a bet on regulatory T cells (Tregs) to combat neurodegenerative diseases. The company's market cap reflects its belief in its approach to treating diseases like amyotrophic lateral sclerosis (ALS). Its performance is a barometer of hope for a breakthrough in one of the most challenging areas of medicine.
COYA - Share of the company's market capitalization Coya Therapeutics Inc. within the market segment - Neuro
Coya Therapeutics' stake in the neuroscience sector is a bet on an innovative approach to treating neurodegenerative diseases. The company focuses on regulatory T-cell therapy. Its market share reflects investors' confidence in the potential of this cutting-edge approach to treating diseases like ALS.
Market capitalization of the market segment - Neuro
Coya Therapeutics develops regulatory T-cell therapy for the treatment of neurodegenerative and autoimmune diseases. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect hopes for breakthroughs in the treatment of these complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Coya Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative and autoimmune diseases. Its market capitalization reflects the hope for breakthroughs in these complex areas. The chart below shows the economic weight of companies at the forefront of neuroscience.
Book value capitalization of the company, segment and market as a whole
COYA - Book value capitalization of the company Coya Therapeutics Inc.
Coya Therapeutics is a biopharmaceutical company. Its book value represents its R&D capital. The chart below shows its financial resources for developing therapies for neurodegenerative diseases. This level is an indicator of its ability to fund clinical trials.
COYA - Share of the company's book capitalization Coya Therapeutics Inc. within the market segment - Neuro
Coya Therapeutics is a clinical-stage biotech company developing therapies for neurodegenerative diseases. Its value lies in its scientific platform. Its tangible asset share will be minimal, typical for R&D companies whose primary capital is intellectual property.
Market segment balance sheet capitalization - Neuro
Coya Therapeutics is a clinical-stage biotech company. Its value is created in laboratories developing T-cell-based therapies. This is a "light" model. The chart below shows how much the biopharmaceutical industry as a whole relies on physical assets versus intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Coya Therapeutics' assets represent capital invested in the development of innovative cell therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The book value reflects the investment in this complex but potentially breakthrough area of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell-based therapies for the treatment of neurodegenerative diseases. Its value lies in its scientific platform, not its tangible assets. Its market capitalization reflects its hopes for breakthroughs in the treatment of diseases such as amyotrophic lateral sclerosis (ALS).
Market to book capitalization ratio in a market segment - Neuro
Coya Therapeutics is a clinical-stage biotech focused on treating neurodegenerative diseases. It has no commercial products. Its value is a bet on the success of its research. The chart demonstrates the significant premium investors are paying for the hope of developing an effective treatment.
Market to book capitalization ratio for the market as a whole
Coya Therapeutics is a clinical-stage biotech company developing therapies for neurodegenerative and autoimmune diseases. The chart shows how the market values this new approach to treating complex diseases. The company's market capitalization is a bet on the success of its scientific research and is not tied to its small tangible assets.
Debts of the company, segment and market as a whole
COYA - Company debts Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing cell therapies for the treatment of neurodegenerative and autoimmune diseases. Currently in the clinical stage, the company uses raised capital to fund its expensive and innovative research, as reflected in the financial strategy in this chart.
Market segment debts - Neuro
Coya Therapeutics is a biopharmaceutical company developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. This is a cutting-edge cell therapy. The chart shows the financial norms for the biotech sector, where companies are raising massive amounts of capital to fund their complex and innovative clinical programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Funding breakthrough, yet risky, medical research is its primary focus. This chart shows the role of debt in this funding, directly reflecting the level of financial risk for the company and its investors.
Market segment debt to market segment book capitalization - Neuro
Developing cell therapies for neurodegenerative and autoimmune diseases, a focus of Coya Therapeutics, requires significant investment. This chart shows how the biotech sector funds its research. It allows one to appreciate how Coya's financial model, which works with regulatory T cells, differs from other players in this complex market.
Debt to book value of all companies in the market
Coya Therapeutics develops treatments for neurodegenerative diseases using regulatory T cells. Like any early-stage biotech company, it requires significant capital. The chart shows how its financial commitments for research compare to the overall market debt level.
P/E of the company, segment and market as a whole
P/E - Coya Therapeutics Inc.
This chart shows the valuation of Coya Therapeutics, Inc., a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases. Its value is determined not by current earnings, but by investors' faith in its scientific approach. The chart reflects the company's hopes for effective treatments for diseases such as amyotrophic lateral sclerosis.
P/E of the market segment - Neuro
This metric represents the average valuation for the biotech sector in which Coya Therapeutics operates. In this industry, which is full of research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding treatments for neurodegenerative diseases.
P/E of the market as a whole
Coya Therapeutics is developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. This is a cutting-edge, yet experimental, approach in medicine. This chart illustrates the market's appetite for risk in biotech. It helps understand how investors view the scientific complexity and potential of Coya's platform for treating diseases such as amyotrophic lateral sclerosis (ALS).
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS). The company's future depends on the success of this cell therapy in the clinic. This chart reflects investor speculative expectations for its innovative treatment approach.
%20P%2FE%20Coya%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Coya-Therapeutics-Inc.&v=1772702513574 "Chart of the company's future (projected) P/E Coya Therapeutics Inc.")
Future (projected) P/E of the market segment - Neuro
Coya Therapeutics is a clinical-stage biotech company developing T-regulatory cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This chart reflects expectations for the biotech sector, providing context for assessing the market's perception of this complex and innovative cell therapy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772702513585 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This chart of overall expectations reflects investor sentiment toward innovative treatments. Market optimism and risk appetite are essential for funding such cutting-edge, yet experimental, therapeutic approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702513588 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Coya Therapeutics Inc.
Coya Therapeutics is a clinical-stage biotechnology company focused on developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This chart shows the cost of innovative research. Revenue is dependent on the future success of clinical trials and approval of this cutting-edge treatment approach.
Profit of companies in the market segment - Neuro
Inspirato Incorporated offers a subscription model for luxury travel, providing access to a portfolio of luxury villas and hotels. Profitability depends on the ability to manage high-end assets and retain subscribers. This chart shows how subscription-based business models are penetrating the travel sector, but high operating costs make the path to profitability challenging.
Overall market profit
Coya Therapeutics is a biotech company developing regulatory T cell-based therapies for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis. Its success is entirely dependent on the results of clinical trials. It is an example of a business focused on scientific breakthroughs that could change the treatment paradigm for serious diseases.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. Its profit outlook is long-term and depends entirely on the success of clinical trials. This chart shows analysts' speculative expectations regarding the potential of cell therapy in neurology.
%20profit%20of%20the%20company%20Coya%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Coya-Therapeutics-Inc.&v=1772702513731 "Graph of future (projected) profit of the company Coya Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Coya Therapeutics is developing T-regulatory cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This is a cutting-edge approach aimed at restoring balance to the immune system. This chart shows profitability projections for the biotech sector. It reflects the potential of cell therapy to treat today's most complex diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772702513748 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Its prospects depend on clinical success. However, the overall profit projections presented in this chart are important for assessing the investment climate. They influence investor willingness to fund long-term, high-risk biotech projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702513789 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. Being in the early stages, it has no commercial revenue. The chart reflects investor sentiment for its innovative approach, which aims to restore balance to the immune system.
P/S market segment - Neuro
Coya Therapeutics, Inc. is a clinical-stage biotechnology company developing regulatory T cell (Treg)-based therapies for neurodegenerative and autoimmune diseases. This chart shows the average valuation for the sector, providing insight into the market's perception of the revenue potential of Coya's innovative cell therapy.
P/S of the market as a whole
Coya Therapeutics develops therapies based on regulatory T cells (Tregs) for the treatment of neurodegenerative and autoimmune diseases. This is at the forefront of cell therapy. This chart, showing average valuations, clearly demonstrates the gap between the valuations of companies with current sales and the value of scientific platforms with long-term potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This chart shows investor confidence in the future success of this approach. The valuation is based on expectations for clinical trials that could lead to breakthrough drugs.
%20P%2FS%20Coya%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Coya-Therapeutics-Inc.&v=1772702513977 "The graph of the company's future (projected) P/S Coya Therapeutics Inc.")
Future (projected) P/S of the market segment - Neuro
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis. The chart shows how investors estimate Coya's future sales, reflecting the high potential and risks associated with cell therapy.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772702514019 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Investor optimism about future earnings hinges on new approaches to treating neurodegenerative diseases. Coya Therapeutics is developing regulatory T cell-based therapies to combat diseases such as amyotrophic lateral sclerosis. Their innovative approach raises hopes that effective treatments will be found for these devastating conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702514048 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Coya Therapeutics Inc.
Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. The company does not currently have commercial sales revenue. Its financial chart reflects revenue from collaborations and investments in its cutting-edge research.
Sales of companies in the market segment - Neuro
Coya Therapeutics develops therapies based on regulatory T cells (Tregs) to combat neurodegenerative and autoimmune diseases. This chart shows total revenue in the neuroscience pharmaceutical segment. It illustrates the search for new approaches to treating complex diseases, where Coya is focusing on advanced cell therapies to restore immune system balance.
Overall market sales
Coya Therapeutics is a clinical-stage biotech developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. Its value lies in the potential of its innovative approach. This dynamic economic climate impacts the availability of venture capital to fund breakthrough, yet risky, medical research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. The future depends on the success of clinical trials. The chart shows speculative analyst forecasts, which are betting on a breakthrough in the treatment of diseases such as amyotrophic lateral sclerosis.
%20sales%20of%20the%20company%20Coya%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Coya-Therapeutics-Inc.&v=1772702514079 "Schedule of future (projected) sales of the company Coya Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Neuro
Coya Therapeutics is a biotech company developing cell therapies based on regulatory T cells (Tregs) for the treatment of neurodegenerative and autoimmune diseases. Its success depends on clinical data. This chart reflects forecasts for the entire neurological pharmaceutical segment, showing analysts' overall expectations for the development of this medical field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772702514090 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell-based therapies for the treatment of neurodegenerative diseases. Its future depends on the success of its research. This overall economic climate impacts the investment climate and risk appetite, which determine the availability of funding for such cutting-edge projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702514106 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Coya Therapeutics Inc.
Coya Therapeutics is a biotech company developing regulatory T cell-based therapies for the treatment of neurodegenerative diseases. This metric reflects its financial position at the R&D stage and demonstrates the level of investment in research required to advance its innovative approach through clinical trials.
Market segment marginality - Neuro
Coya Therapeutics is a clinical-stage biotechnology company developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. This metric reflects its operational structure and level of investment in advanced cell therapy compared to other neuroscience companies.
Market marginality as a whole
Coya Therapeutics is a clinical-stage biotech developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. Their future depends on the success of clinical trials. This overall profitability curve is not directly relevant to them, but it does impact the overall environment and availability of funding in the biotech sector.
Employees in the company, segment and market as a whole
Number of employees in the company Coya Therapeutics Inc.
Coya Therapeutics is a biotech company working on regulatory T cells for the treatment of neurodegenerative and autoimmune diseases. Being in the early clinical stage, it has a compact team. This chart shows the dynamics of the scientific team focused on advancing its innovative cell therapy.
Share of the company's employees Coya Therapeutics Inc. within the market segment - Neuro
Coya Therapeutics is developing regulatory T cell-based therapies for the treatment of neurodegenerative and autoimmune diseases. This chart shows the concentration of leading immunologists and neurologists. This proportion reflects its innovative approach to treating diseases such as amyotrophic lateral sclerosis.
Number of employees in the market segment - Neuro
Coya Therapeutics, Inc. is a biotechnology company developing T-regulatory cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This chart shows overall employment in the neuroscience sector. It illustrates the cutting edge of science, where Coya is harnessing the immune system's natural mechanisms to combat severe diseases.
Number of employees in the market as a whole
Coya Therapeutics is a biotech company developing therapies based on regulatory T cells (Tregs) for the treatment of neurodegenerative and autoimmune diseases. This innovative approach to immunology is at the forefront of this company's workforce. This overall employment chart also reflects the contributions of science-intensive startups, where every employee is a valuable contributor to the creation of the medicine of the future.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Coya Therapeutics Inc. (COYA)
Coya Therapeutics, Inc. is a biotech company developing therapies for neurodegenerative and autoimmune diseases. This chart is a classic example of a clinical biotech company. The very high market capitalization per employee demonstrates that investors value the scientific potential and intellectual property generated by a small but highly effective team.
%20of%20the%20company%20Coya%20Therapeutics%20Inc.%20(COYA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Coya-Therapeutics-Inc.-COYA&v=1772702514251 "Chart of market capitalization per employee (in thousands of dollars) of the company Coya Therapeutics Inc. (COYA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Coya Therapeutics is a biotech company working on therapies for neurodegenerative diseases. Their market cap is based on clinical trial expectations. This metric demonstrates the enormous potential value the market places on their research team. This high value reflects hopes for breakthrough treatments for diseases like ALS.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772702514259 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Coya Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and autoimmune diseases. Its valuation is determined by the potential of its scientific developments. The high valuation per employee reflects investors' bet that a small scientific team can succeed where many have failed.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702514274 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Coya Therapeutics Inc. (COYA)
Coya Therapeutics is a biotech R&D company focused on regulatory T cells (Tregs) for the treatment of neurodegenerative and autoimmune diseases. It's pure science. This chart shows the net loss (investment in preclinical and clinical research) per scientist.
%20Chart%20Coya%20Therapeutics%20Inc.%20(COYA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Coya-Therapeutics-Inc.-COYA&v=1772702514283 "Company Profit Per Employee (in thousands of dollars) Chart Coya Therapeutics Inc. (COYA)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Coya Therapeutics is a clinical-stage biotech company working on the treatment of neurodegenerative diseases. As with other R&D firms, this timeline is a goal for the future. Currently, all of their value lies in the intellectual potential of their research team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772702514304 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Coya Therapeutics (COYA) is a biotech company working on regulatory T cells (Tregs) for the treatment of neurodegenerative and autoimmune diseases. This is cutting-edge science. This graph shows that the company is in the R&D stage. Every scientist employed is an investment in future therapy, which means negative profits today.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702514322 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Coya Therapeutics Inc. (COYA)
For Coya Therapeutics, a biotech company developing therapies for neurodegenerative diseases, this graph reflects the clinical trial stage. Future revenue growth per employee depends entirely on the success of its innovative approaches and subsequent drug commercialization.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Coya-Therapeutics-Inc.-COYA&v=1772702514372 "Sales chart per company employee Coya Therapeutics Inc. (COYA)")
Sales per employee in the market segment - Neuro
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative and autoimmune diseases. This R&D metric reflects the average revenue per employee for the segment. It helps assess how productive their research team is in advancing this complex therapy compared to competitors.
Sales per employee for the market as a whole
Coya Therapeutics (COYA) is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative and autoimmune diseases. Currently, its staff consists entirely of researchers. This metric is critical for COYA: it's at zero. Its future growth will signal the success of its R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Coya Therapeutics Inc. (COYA)
Coya Therapeutics is an early-stage biotech focused on regulatory T cells (Tregs) for the treatment of neurodegenerative diseases like ALS. This is a highly complex and risky field. This chart reflects investor bets that its scientific approach will fail in clinical trials, a common occurrence for ALS therapies.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Coya-Therapeutics-Inc.-COYA&v=1772702514425 "Short Shares Chart for the Company Coya Therapeutics Inc. (COYA)")
Shares shorted by market segment - Neuro
Coya Therapeutics (COYA) is a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases using regulatory T cells. This chart shows the overall short position in the speculative cell therapy sector, reflecting the high skepticism regarding the viability and effectiveness of this approach for complex diseases.
Shares shorted by the overall market
Coya Therapeutics (COYA) is a clinical-stage biotech company. Its value reflects its hope for future success. When this overall pessimism indicator rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, as they need to refinance R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Coya Therapeutics Inc. (COYA)
Coya Therapeutics (COYA) is a biotech company working in the complex field of neurodegenerative diseases (ALS). This is a high-risk bet on their R&D. This chart measures the extremes of speculative sentiment. It shows when the stock is "overbought" on positive data or "oversold" on news of delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Coya-Therapeutics-Inc.-COYA&v=1772702514441 "RSI 14 indicator chart for the company's stock Coya Therapeutics Inc. (COYA)")
RSI 14 Market Segment - Neuro
Coya (COYA) is a biotech company that boosts immunity. They are developing therapies based on *regulatory T cells* (Tregs) to treat *neurodegenerative* (ALS) and *autoimmune* diseases. The "Neuro" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It is vital to understand: is COYA's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
Coya Therapeutics (COYA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast COYA (Coya Therapeutics Inc.)
Coya Therapeutics is a biotech company developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative diseases such as ALS. This chart shows the speculative average price target from analysts based on their assessment of this advanced R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-COYA-Coya-Therapeutics-Inc.&v=1772702514573 "A chart showing analyst consensus forecasts for the expected stock price. COYA (Coya Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price COYA (Coya Therapeutics Inc.)
Coya Therapeutics is a biotech company focused on developing regulatory T cell (Treg)-based therapies for the treatment of neurodegenerative diseases such as ALS. This chart measures the gap between the current stock price and the consensus target price. It shows whether experts believe in this complex yet innovative approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-COYA-Coya-Therapeutics-Inc.&v=1772702514584 "A chart showing the difference between the consensus forecast and the actual stock price. COYA (Coya Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Coya Therapeutics (COYA) is a biotech company developing therapies based on "regulatory T cells" (Tregs) for the treatment of neurodegenerative diseases such as ALS. This chart shows the overall expectations for the neuroscience sector, reflecting the confidence of experts in this complex cell-based treatment approach.
Analysts' consensus forecast for the overall market share price
Coya Therapeutics is a biotech company developing treatments for neurodegenerative diseases (ALS) by targeting regulatory T cells. This chart shows overall risk appetite. For Coya, operating in the most complex area of medicine, overall market optimism is critical to funding multi-year, expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Coya Therapeutics Inc.
Coya (COYA) is a clinical-stage biotech focused on neurodegeneration (ALS). Their specialty is regulatory T cells (Tregs), which attempt to suppress inflammation in the brain that kills neurons. This chart represents pure R&D betting. Its valuation reflects the market's faith in their (very early) scientific platform and their trial data.
AKIMA Market Segment Index - Neuro
Coya Therapeutics is a biotech company developing therapies based on regulatory T cells (Tregs) for the treatment of neurodegenerative diseases such as ALS. This chart shows the average index for the neuro segment. It provides investors with a benchmark for how Coya Therapeutics' performance compares to the sector average.
The AKIM Index for the overall market
Coya Therapeutics is a biotech company developing therapies that modulate regulatory T cells (Tregs) to combat neurodegeneration (ALS). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story fits in with overall economic trends and interest in new mechanisms.
